Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694069 · ClinicalTrials.gov registry record · Phase 4
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
A Phase 4 study, sponsored by West Virginia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT01694069 is a Phase 4 study that was terminated before completion, run by West Virginia University. The registered enrollment target is 6 participants.
The verdict
NCT01694069, a Phase 4 study, was terminated before completion, sponsored by West Virginia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs. One of the most common and harmful bacteria is called Pseudomonas aeruginosa. Patients with cystic fibrosis require frequent therapy with intravenous (I.V.) antibiotics to treat lung infections thought to be caused by Pseudomonas aeruginosa. One of the antibiotics frequently used to treat this bacteria is piperacillin-tazobactam. Piperacillin-tazobactam is thought to be the most effective when there is a constant level of drug in the body. The standard way to administer piperacillin-tazobactam is to give several grams 4 times each day as a 30 minute infusion. An alternative way to give piperacillin-tazobactam is by a continuous infusion; a continuous infusion will make it more likely that drug will remain at a constant level in the body. The objective of this study is to determine if administering piperacillin-tazobactam as a continuous infusion is more effective at treating people having a pulmonary exacerbation of cystic fibrosis than a standard 30 minute infusion, 4 times a day.
Interventions
- DRUG Piperacillin-tazobactam combination product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01694069
The ClinicalTrials.gov registry entry for NCT01694069 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Piperacillin-tazobactam combination product is the first listed.
NCT01694069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01694069 about?
NCT01694069 is a clinical study titled "Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis". Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs. One of the most common and harmful bacteria is called Pseudomonas aeruginosa. Patients with cystic f...
What is the current status of trial NCT01694069?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2012-09. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01694069?
The interventions under investigation include: Piperacillin-tazobactam combination product (DRUG).
Who is sponsoring clinical trial NCT01694069?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.